GlobeNewsWire
13 Jul 2026, 06:30 UTC · 2h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
3 claims · each scored for market impact
Alamar Biosciences will deploy its NULISAseq Neuro 220 panel to profile ~21,000 plasma samples from 10,000 participants in a national neurodegenerative disease initiative. — This represents a significant commercial application and validation event for Alamar's core proteomics platform at a national scale.
+0.60The initiative includes the addition of a new eMTBR-Tau assay to the Neuro 220 panel, enabling blood-based representation of tau tangle burden. — Product expansion into high-value tau biomarkers increases the competitive utility of their proteomics offering.
+0.40The resulting proteomic dataset will be made publicly accessible and linked to National Alzheimer’s Coordinating Center IDs for AI-driven discovery. — While promoting open science, this expands the visibility of Alamar's technology among the global research and AI community.
+0.20Which stocks this story touches
Continue reading
6 related stories
Top 2 movers · tap to explore
The company announced a major national-scale partnership and initiative utilizing its proprietary NULISAseq Neuro 220 panel for Alzheimer's research.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
PRNewsWire
4h ago
